David J. McConkey

Active 1987–2026

201
Papers
40,008
Citations
108
h-index
196
i10-index

Citations

Citations per year for David J. McConkey1945: 1 citations1982: 1 citations1989: 43 citations1990: 75 citations1991: 156 citations1992: 206 citations1993: 189 citations1994: 152 citations1995: 171 citations1996: 165 citations1997: 142 citations1998: 175 citations1999: 171 citations2000: 228 citations2001: 172 citations2002: 230 citations2003: 248 citations2004: 273 citations2005: 259 citations2006: 250 citations2007: 218 citations2008: 218 citations2009: 250 citations2010: 271 citations2011: 249 citations2012: 293 citations2013: 235 citations2014: 290 citations2015: 279 citations2016: 271 citations2017: 271 citations2018: 319 citations2019: 1,230 citations2020: 1,250 citations2021: 1,197 citations2022: 941 citations2023: 713 citations2024: 1,098 citations2025: 516 citations2026: 17 citations1946–1981: no citations, so these years are not shown1983–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,239 citing papers, 31.4% of this breakdownChina: 1,602 citing papers, 11.9% of this breakdownUnited Kingdom: 725 citing papers, 5.4% of this breakdownGermany: 676 citing papers, 5% of this breakdownItaly: 582 citing papers, 4.3% of this breakdownCanada: 486 citing papers, 3.6% of this breakdownFrance: 485 citing papers, 3.6% of this breakdownJapan: 444 citing papers, 3.3% of this breakdownSpain: 403 citing papers, 3% of this breakdownNetherlands: 286 citing papers, 2.1% of this breakdownSouth Korea: 280 citing papers, 2.1% of this breakdownAustralia: 247 citing papers, 1.8% of this breakdown
0%31.4%Other 22.5%

Fields

  • Medicine46.2%
  • Biochemistry, Genetics and Molecular Biology42.9%
  • Immunology and Microbiology4.5%
  • Neuroscience1.8%
  • Engineering0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Other3.2%

Topics

  • Bladder and Urothelial Cancer Treatments6.8%
  • Cell death mechanisms and regulation3.3%
  • Urinary and Genital Oncology Studies2.8%
  • Epigenetics and DNA Methylation2.7%
  • Autophagy in Disease and Therapy2.1%
  • Cancer Cells and Metastasis2%
  • Other80.3%

Coauthors

All papers

Open in search
  1. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan Bullman, Kristen Leraas, Tara M. Lichtenberg, Catherine J. Wu, N. Schultz, Gad Getz, Matthew Meyerson, Gordon B. Mills, David J. McConkey, Rehan Akbani, Hikmat Al‐Ahmadie, Monique Albert, Iakovina Alexopoulou, Adrian Ally, Tatjana Antic, Manju Aron, Miruna Balasundaram, John M.S. Bartlett, Stephen B. Baylin, Allison Beaver, Joaquim Bellmunt, İnanç Birol, Lori Boice, Moiz S. Bootwalla, Jay Bowen, Reanne Bowlby, Denise Brooks, Bradley M. Broom, Wiam Bshara, Susan Bullman, Eric Burks, Flavio Mavignier Cárcano, Rebecca Carlsen, Benilton S. Carvalho, André Lopes Carvalho, Eric Castle, Mauro A. A. Castro, Patricia Castro, James W.F. Catto, Vinicius S Chagas, Andrew D. Cherniack, David Chesla, Caleb Choo, Eric Chuah, Sudha Chudamani, Victoria K. Cortessis, Sandra Cottingham, Daniel Crain, Erin Curley, Bogdan Czerniak, Siamak Daneshmand, John A. Demchok, Noreen Dhalla, Hooman Djaladat, John Eckman, Sophie Egea, Jay Engel, Ina Felau, Martin L. Ferguson, Johanna Gardner, Julie M. Gastier‐Foster, Mark Gerken, Gad Getz, Ewan A. Gibb, Carmen Gomez‐Fernandez, Dmitry A. Gordenin, Guangwu Guo, Donna E. Hansel, Jodi Harr, Arndt Hartmann and 113 more - Cell 2017 cited by 2,535

  2. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mattias Aine, Hikmat Al-Ahmadie, Yves Allory, Joaquim Bellmunt, Isabelle Bernard-Pierrot, Peter C. Black, Mauro A.A. Castro, Keith Syson Chan, Woonyoung Choi, Bogdan Czerniak, Colin P. Dinney, Lars Dyrskjøt, Pontus Eriksson, Jacqueline Fontugne, Ewan A. Gibb, Clarice S. Groeneveld, Arndt Hartmann, Katherine A. Hoadley, Mattias Höglund, Aurélie Kamoun, Jordan Kardos, Jaegil Kim, William Y. Kim, David J. Kwiatkowski, Thierry Lebrét, Seth P. Lerner, Fredrik Liedberg, Núria Malats, David J. McConkey, Qianxing Mo, Thomas Powles, François Radvanyi, Francisco X. Real, Aurélien de Reyniès, A. Gordon Robertson, Arlene O. Siefker‐Radtke, Nanor Sirab, Roland Seiler, Gottfrid Sjödahl, Ann Taber, John N. Weinstein, Alexandre Zlotta - European Urology 2019 cited by 1,360

  3. Comprehensive molecular characterization of urothelial bladder carcinoma Open

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David J. Kwiatkowski, Andrew D. Cherniack, Weiguo Jian, Chandra Sekhar Pedamallu, Richard C. Gibbs, Seth P. Lerner, Kristian Cibulskis, Patricia Garrido Castro, Andrey Sivachenko, Chip Stewart, Michael S. Lawrence, Whitney D. McClenden, Margaret Morgan, Richard C. Gibbs, Scott L. Carter, Chad J. Creighton, Lawrence A. Donehower, Chad J. Creighton, C. Smith, Ami S. Bhatt, Trevor Pugh, Gordon Saksena, Lee Lichtenstein, Michael S. Lawrence, Carrie Sougnez, Kristian Cibulskis, Daniel DiCara, Petar Stojanov, Steven E. Schumacher, Doug Voet, Yingchun Liu, Jaegil Kim, Petar Stojanov, Doug Voet, Pei Lin, Hailei Zhang, Scott L. Carter, Scott Frazer, Michael S. Noble, Daniel DiCara, Lihua Zou, Bernard H. Bochner, Nils Gehlenborg, Ilana R. Garcia-Grossman, David I. Heiman, Juok Cho, Rameen Beroukhim, Dmitry A. Gordenin, David J. Kwiatkowski, Ami S. Bhatt, Andrey Sivachenko, Joonil Jung, Chip Stewart, Andrew D. Cherniack, Samuel S. Freeman, Eric Lander, Michael S. Noble, Tod D. Casasent, David J. Van Den Berg, David J. Kwiatkowski, Nikolaus Schultz, David J. Kwiatkowski, Jianjiong Gao, Anders Jacobsen, B. Arman Aksoy, Ami S. Bhatt, Petar Stojanov, Chandra Sekhar Pedamallu, Rameen Beroukhim, William Lee and 194 more - Nature, Nat. 2014 cited by 3,086

  4. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2014 cited by 1,741

  5. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan L. Wright, Marc Dall’Era, Michiel S. van der Heijden, Peter C. Black - European Urology 2017 cited by 792

  6. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes

    Authors: , , , , , , , , , , - Applied immunohistochemistry & molecular morphology 2021 cited by 153

  7. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

    Authors: , , , , , , , , , , , , , , - European Urology 2023 cited by 91

  8. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2015 cited by 541

  9. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19

    Authors: , , , , , , , , , , , , , - Nature Reviews Urology 2021 cited by 147

  10. Autophagy as a target for anticancer therapy

    Authors: , , , - Nature Reviews Clinical Oncology 2011 cited by 809

  11. Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

    Authors: , , , , , , , , , - Cancer Research 2009 cited by 862

  12. Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , - Science 2011 cited by 595

  13. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

    Authors: , , , , , , , , , - Nature Reviews Urology 2020 cited by 195

  14. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan Bullman, Kristen M. Leraas, Tara M. Lichtenberg, Catherine J. Wu, N. Schultz, Gad Getz, Matthew Meyerson, Gordon B. Mills, David J. McConkey, John N. Weinstein, David J. Kwiatkowski, Seth P. Lerner - Cell 2018 cited by 587

  15. The consensus molecular classification of muscle-invasive bladder cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , The Bladder Cancer Molecular Taxonomy Group - 2018 cited by 152

  16. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 123

  17. RETRACTED ARTICLE: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

    Authors: , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 97

  18. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

    Authors: , , , , , , , , , , , , , , , - EBioMedicine 2016 cited by 342

  19. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elizabeth R. Plimack, M.A. Hallman, Eric M. Horwitz, Essel Dulaimi Al-Saleem, David Y.T. Chen, Richard E. Greenberg, Alexander Kutikov, Gordon Guo, Timothy A. Masterson, Nabil Adra, Hristos Z. Kaimakliotis - European Urology 2023 cited by 55

  20. Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 166

  21. Identification of Differential Tumor Subtypes of T1 Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , - European Urology 2020 cited by 159

  22. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2019 cited by 151

  23. Molecular profile of bladder cancer progression to clinically aggressive subtypes

    Authors: , , , , , , , , - Nature Reviews Urology 2024 cited by 78

  24. Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

    Authors: , , , , , , - European Urology Open Science 2023 cited by 45